glp-1 obesity drug news october 21 2025 In U.S., Usage Reaches New High GLP-1 drug coverage for obesity

F., Lingvay, I., & Kushner, R

Zhang LQ, Zhang W, Li T, Yang T, Yuan X, Zhou Y, Zou Q, Yang H, Gao F, Tian Y, Mei W, Tian XB (2021) GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-kappaB pathway in neuropathic pain mice

Expect a transition period

These include In 2023, Deanfield and his research team published research findings that found semaglutide the active ingredient in GLP-1 medications Wegovy and Ozempic could potentially reduce a persons risk for heart attack, stroke, and major cardiac events by 20%

This session explores what sustainable maintenance looks like in the real world, including lower-dose, longer-duration treatment strategies, and asks what long-term health outcomes, from cardiovascular risk to metabolic function, become possible when treatment is truly sustained

For detailed mechanisms, see our guide: How Does Retatrutide Work